393 related articles for article (PubMed ID: 35122038)
1. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer.
Oh SA; Wu DC; Cheung J; Navarro A; Xiong H; Cubas R; Totpal K; Chiu H; Wu Y; Comps-Agrar L; Leader AM; Merad M; Roose-Germa M; Warming S; Yan M; Kim JM; Rutz S; Mellman I
Nat Cancer; 2020 Jul; 1(7):681-691. PubMed ID: 35122038
[TBL] [Abstract][Full Text] [Related]
2. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
3. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
4. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
[TBL] [Abstract][Full Text] [Related]
5. Restriction of PD-1 function by
Sugiura D; Maruhashi T; Okazaki IM; Shimizu K; Maeda TK; Takemoto T; Okazaki T
Science; 2019 May; 364(6440):558-566. PubMed ID: 31000591
[TBL] [Abstract][Full Text] [Related]
6. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells.
Dilek N; Poirier N; Hulin P; Coulon F; Mary C; Ville S; Vie H; Clémenceau B; Blancho G; Vanhove B
PLoS One; 2013; 8(12):e83139. PubMed ID: 24376655
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer.
Krempski J; Karyampudi L; Behrens MD; Erskine CL; Hartmann L; Dong H; Goode EL; Kalli KR; Knutson KL
J Immunol; 2011 Jun; 186(12):6905-13. PubMed ID: 21551365
[TBL] [Abstract][Full Text] [Related]
9. The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion.
Hofmeyer KA; Jeon H; Zang X
J Biomed Biotechnol; 2011; 2011():451694. PubMed ID: 21960736
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
Duraiswamy J; Freeman GJ; Coukos G
Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
[TBL] [Abstract][Full Text] [Related]
11. Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
[TBL] [Abstract][Full Text] [Related]
12. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.
Hui E; Cheung J; Zhu J; Su X; Taylor MJ; Wallweber HA; Sasmal DK; Huang J; Kim JM; Mellman I; Vale RD
Science; 2017 Mar; 355(6332):1428-1433. PubMed ID: 28280247
[TBL] [Abstract][Full Text] [Related]
13. Lymph node and tumor-associated PD-L1
Sprooten J; Vanmeerbeek I; Datsi A; Govaerts J; Naulaerts S; Laureano RS; Borràs DM; Calvet A; Malviya V; Kuballa M; Felsberg J; Sabel MC; Rapp M; Knobbe-Thomsen C; Liu P; Zhao L; Kepp O; Boon L; Tejpar S; Borst J; Kroemer G; Schlenner S; De Vleeschouwer S; Sorg RV; Garg AD
Cell Rep Med; 2024 Jan; 5(1):101377. PubMed ID: 38232703
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Binds to B7-1 Only
Chaudhri A; Xiao Y; Klee AN; Wang X; Zhu B; Freeman GJ
Cancer Immunol Res; 2018 Aug; 6(8):921-929. PubMed ID: 29871885
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1.
Ramaswamy M; Kim T; Jones DC; Ghadially H; Mahmoud TI; Garcia A; Browne G; Zenonos Z; Puplampu-Dove Y; Riggs JM; Bhat GK; Herbst R; Schofield DJ; Carlesso G
Cancer Immunol Res; 2022 Feb; 10(2):200-214. PubMed ID: 34937728
[TBL] [Abstract][Full Text] [Related]
16. Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor.
McCarthy D; Lofgren M; Watt A; Horton H; Kieffer-Kwon P; Ding J; Kobold S; Baeuerle PA; Hofmeister R; Gutierrez DA; Tighe R
Cancer Immunol Immunother; 2023 Dec; 72(12):4195-4207. PubMed ID: 37848682
[TBL] [Abstract][Full Text] [Related]
17. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.
Mayoux M; Roller A; Pulko V; Sammicheli S; Chen S; Sum E; Jost C; Fransen MF; Buser RB; Kowanetz M; Rommel K; Matos I; Colombetti S; Belousov A; Karanikas V; Ossendorp F; Hegde PS; Chen DS; Umana P; Perro M; Klein C; Xu W
Sci Transl Med; 2020 Mar; 12(534):. PubMed ID: 32161104
[TBL] [Abstract][Full Text] [Related]
19. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
[TBL] [Abstract][Full Text] [Related]
20. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
